Seres Therapeutics is no longer the company that took the first oral microbiome drug through Food and Drug Administration approval. That franchise, VOWST, left the building in September 2024 when Nestlé Health Science bought the business, and the remaining public equity is a Cambridge clinical-stage leftover trying to turn a live bacterial consortium called SER-155 into a second act. The second-quarter print looks profitable only because Nestlé agreed in June to pay a fixed buyout in place of contingent sales milestones. Underneath that accounting gain, operations still consume cash, the Phase 2 study in transplant patients sits paused for lack of funding, and the latest quarterly report states outright that current resources raise substantial doubt about the ability to continue as a going concern.
The investment debate is whether a partner or a new financing arrives before the cash clock expires, and whether the July investigator-sponsored readout in checkpoint-inhibitor colitis is enough to make that conversation real. Twelve of fifteen Memorial Sloan Kettering patients met the study's immunosuppressive-free response definition at day fifteen, and the company is now shopping the program to oncology franchises that already sell checkpoint inhibitors. That is a genuine scientific opening. It is also a fifteen-patient, open-label, investigator-run dataset with no control arm, and the day-forty-three durability was thinner than the headline. Meanwhile Richard Kender, a long-time director with a Merck business-development résumé, took the interim chief executive seat in March specifically to sell or fund the pipeline. The market is pricing the residual claim near the cash-plus-receivable floor after a one-for-twenty reverse split last April and a year that took the shares from the high twenties down to a four-handle close.
What resolves the argument is not another cost cut. Lease exits and a February headcount reduction already bought months, not a franchise. The variables that matter are whether a named partner funds SER-155 in either transplant infection prevention or checkpoint colitis, whether the October Nestlé installment arrives on schedule, and whether the at-the-market program can raise capital at a price that does not collapse the remaining float. Absent those, the equity is a short-dated option on a paused Phase 2 asset and a small, unblinded colitis signal.